

**CHAIR'S KEY ISSUES**

**ISSUES FOR REFERRING/ESCALATING TO BOARD OF DIRECTORS**

**PART A:**

<b>ORIGINATING COMMITTEE OR GROUP:</b>		Quality and Performance Committee	<b>DATE OF MEETING ISSUE RAISED:</b>		16 February 2017
<b>CHAIR:</b>		Graham Hodgson	<b>LEAD EXECUTIVE DIRECTOR:</b>		Medical Director
<b>Agenda Item No.</b>	<b>DETAILS OF ISSUE:</b>	<b>FOR - APPROVAL / ESCALATION / ALERT / ASSURANCE / INFORMATION</b>	<b>RISK REGISTER / BAF REFERENCE</b>	<b>PAPER ATTACHED</b> √	
2.1 Cancer referrals and NG12	The Committee received a progress report from the Cancer Services Directorate on the potential impact of NICE guidance (NG12) on cancer referrals and its potential impact on RTT and cancer pathways. There remains uncertainty about CCG commissioning intentions which the Chief Executive will escalate	Escalation	RR(1) and (11) BAF (1)	Board agenda item 2.6	
5.1 National in-patient survey	The Committee was advised that the national in-patient survey results (2016) indicated significant progress from the 2015 survey. A full report and action plan will be made to the Board on publication of the national report	Information		Board agenda item 2.5	
<b>DATE COMPLETED AND FORWARDED TO DIRECTOR OF CORPORATE AFFAIRS:</b>					

**PART B:**

<b>RECEIVING COMMITTEE:</b>		<b>DATE OF MEETING ISSUE CONSIDERED:</b>	
<b>CHAIR:</b>		<b>LEAD EXECUTIVE DIRECTOR:</b>	

<b>Agenda Item No.</b>	<b>RECORD OF CONSIDERATION GIVEN / APPROVAL / RESPONSE / ACTION:</b>

**M**

<b>DATE COMPLETED AND FORWARDED TO CHAIR OF ORIGINATING BOARD / COMMITTEE / TASK &amp; FINISH GROUP:</b>	